Kyverna signs commercial manufacturing deal with ElevateBio for miv-cel; BLA on track for Q4 2026

Kyverna Therapeutics, Inc.

Agreement covers U.S. commercial and global clinical supply of miv-cel, replacing prior clinical deal.
Supports potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
Rolling BLA submission for miv-cel in SPS remains on track for Q4 2026.
ElevateBio achieved >98% clinical manufacturing success rate for miv-cel.
Initial five-year term with automatic renewals; minimum purchase commitments and annual PPI-based price adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.